Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis

Authors

  • M. B. Vyas B. Vyas

Abstract

The purpose of present research work was to formulate and evaluate eye care solution of Naphazoline hydrochloride (Vasoconstrictor) and Pheniramine maleate (Antihistaminic) drug for allergic conjunctivitis. The optimum values of responses for viscous eye care solution formulation was found to be 97.6 cps viscosity, 1759 cps mucoadhesion index and 96.67 % CDR for naphazoline hydrochloride and 93.34% CDR for pheniramine maleate. These could be obtained at lower levels of NaCMC and higher level of HPMCE4M (0.25/0.6%w/w respectively).These viscous eye care solution showed acceptable physicochemical properties. The optimized formulation was found to be stable in one month study and providing prolonged release of the drug over an 8 hr period. Irritation study on rabbit eye revealed that it was non-irritant. All the rabbits' eyes were normal by the end of 5 hour without any redness. There were no other adverse affects on the eyes throughout 8 hours study. This proves that optimized formulations of viscous eye care solution were very effective against common allergic conditions. We have successfully developed viscous eye solution for allergic conjunctivitis which contains 0.25 % NaCMC and 0.60 % HPMCE4M .It was well tolerated and could be used to prolong the therapeutic effectiveness of drug. The developed system is thus a viable alternative to conventional ophthalmic formulations.

Downloads

How to Cite

Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis. (2015). Global Journal of Medical Research, 15(16), 19-34. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Author Biography

M. B. Vyas B. Vyas

M. B. Vyas is a dedicated pharmaceutical researcher affiliated with Sardar Patel University and Indubhai Patel College of Pharmacy & Research Centre in Gujarat, India. With a focus on drug formulation and delivery, he has contributed to the development of innovative dosage forms including eye care solutions, taste-masked tablets, and bilayer tablets incorporating herbal nanocrystals. His work spans areas such as conjunctivitis treatment, iron supplementation, and arthritis management, reflecting a commitment to advancing pharmaceutical sciences through practical and patient-centric solutions.

References

Mihai Bisca (1997) Current therapy of allergic conjunctivitis. 58(11), 828-841. https://doi.org/10.1016/s0011-393x(97)80049-5

Yusuf Ali, Kari Lehmussaari (2006) Industrial perspective in ocular drug delivery. 58(11), 1258-1268. https://doi.org/10.1016/j.addr.2006.07.022

Rathore (2010) An overview and advancement in ocular drug delivery systems. 46, 11-23.

M. Eva, Atourtti del Amo (2008) Eva M.del Amo and Atourtti, ''Current and future ophthalmic drug delivery systems, A Shift to the posterior segment, Drug Discovery Today. 13, 135-143.

D. Maurice, S. Mishima (1984) Ocular Pharmacokinetics. 15, 19-116. https://doi.org/10.1007/978-3-642-69222-2

Ripal gaudana, Saih A.N (2009) Recent perspectives in ocular drug delivery-expert review. 26(5), 1197-1216. https://doi.org/10.1007/s11095-008-9694-0

Maria D.Moya-Ortega Dexamethasone eye drops containing alpha cyclodextrin-based nanogels.

Published

2015-05-11

How to Cite

Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis. (2015). Global Journal of Medical Research, 15(16), 19-34. https://medicalresearchjournal.org/index.php/GJMR/article/view/